Advertisement
Home »

Simplified Assessment Tool Predicts Psoriasis Severity

Nov 02, 2023

REFERENCES & ADDITIONAL READING

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

https://journals.sagepub.com/doi/10.1177/24755303231155118

ABOUT THE EXPERTS

  • Wayne P. Gulliver, MD

    Wayne P. Gulliver, MD
    Professor of Medicine
    Memorial University of Newfoundland
    Newfoundland

    Wayne P. Gulliver, MD, has indicated to Physician’s Weekly that he has received grants/research support from AbbVie, Amgen, Eli Lilly, Novartis, and Pfizer; honoraria for ad boards/invited talks/consultation from AbbVie, Actelion, Amgen, Arylide, Bausch Health, Boehringer, Celgene, Cipher, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, PeerVoice, Pfizer, Sanofi-Genzyme, Tribute, UCB, and Valeant; and clinical trials (study fees) from AbbVie, Asana Biosciences, Astellas, Boehringer Ingelheim, Celgene, CorEvitas/National Psoriasis Foundation, Devonian, Eli Lilly, Galapagos, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, and UCB.

     

Advertisement

MEETING BRIEFS

Advertisement